As of 2023, around 24 percent of women in the United States reported currently having or being treated for depression, compared to 11 percent of men. This statistic shows the percentage of adults in the United States who currently had or were being treated for depression in 2017 and 2023, by gender.

Based on pharmacy claims in 2019, more than twice the amount of females than males were taking antidepressants. This statistic shows the percentage of individuals (excluding those on government-sponsored benefits) who filled a prescription for antidepressants in the U.S. in 2019, by age group and gender.

Based on pharmacy claims of those who filled at least one prescription for mental health medication in 2019, antidepressant use is most prevalent in West Virginia, Kentucky, Vermont, and New Hampshire. This statistic shows the percentage of patients (excluding those on government-sponsored benefits) who filled a prescription for antidepressants in the U.S. in 2019, by state.

Globally, antidepressant usage has been on the rise. As of 2023, among select Organization for Economic Cooperation and Development (OECD) countries, Iceland, Portugal, and the UK were the biggest consumers of antidepressants. At that time, people in Iceland consumed antidepressants at a rate of about *** defined daily doses (DDD) per 1,000 people. Mental health globally Mental health disorders affect a significant proportion of the population, though addressing and understanding the prevalence of mental health is difficult due to regional differences in diagnostic criteria and understandings of mental health. Despite barriers to gathering data on mental health, there have been some global quantitative studies to help better understand certain conditions. It is suggested that mental health is among the top three health concerns among adults worldwide. Estimates propose that about ** percent of the overall population suffers from some mental health or substance use disorder. Depression and anxiety A global survey showed that the largest numbers of people with anxiety resided in locations in South-East Asia and the Americas. However, the highest distribution of cases of depression globally is among populations in South-East Asia and the Western Pacific. Both depression and anxiety disproportionately impact women in all regions of the world.

ObjectiveThe associations between maternal use of antidepressant during pregnancy and preterm birth (PTB) has been the subject of much discussion and controversy. The aim of the present study was to systematically review the association between antidepressant use during pregnancy and the risk of PTB, especially in depressed women.MethodsA computerized search was conducted in PubMed, PsycINFO, and Embase before June 30, 2019, supplemented with a manual search of the reference lists, to identify original research regarding PTB rates in women taking antidepressants during pregnancy. A random-effects model was used to calculate the summarized relative risks (RRs) and 95% confidence intervals (CIs). The potential for publication bias was examined through Begg' s and Egger' s tests.ResultsA total of 2,279 articles were reviewed, 23 of which were selected. The risk of PTB was increased in women with depression [1.58 (1.23−2.04)] and in the general pregnant female population [1.35 (1.11−1.63)] who used antidepressants during pregnancy. Similar results were observed in depressed women treated with selective serotonin reuptake inhibitors (SSRIs) during pregnancy [1.46 (1.32−1.61)]. There was no significantly increased risk of PTB observed with SSRI use in the general pregnant female population [1.25 (1.00−1.57)], and the heterogeneity of these studies was high.ConclusionsThe results of this meta-analysis indicate maternal antidepressant use is associated with a significantly increased risk of PTB in infants. Health care providers and pregnant women must weigh the risk-benefit potential of these drugs when making decisions about whether to treat with antidepressant during pregnancy.

Number in parenthesis is the percentage of ‘any antidepressant’. Sum of percentages adds up to more than 100% due to some pregnancies being exposed to more than one antidepressant in the given period. SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressants; AD, antidepressant.

According to the European health survey, over 11 percent of women older than 65 years consumed antidepressants or stimulants in Spain in 2020. On the other hand, only 3.57 percent of men of that same age used antidepressants or stimulants. The lowest percentage was found in respondents between the ages of 15 and 24 for both genders.

Background: The treatment of depression is a main strategy for suicide prevention in older adults. We aimed to calculate suicide rates by antidepressant prescription patterns in persons aged ≥ 75 years. A further aim was to estimate the contribution of antidepressants to the change in suicide rates over time.Methods: Swedish residents aged ≥ 75 years (N = 1,401,349) were followed between 2007 and 2014 in a national register-based retrospective cohort study. Biannual suicide rates were calculated for those with selective serotonin reuptake inhibitor (SSRI) single use, mirtazapine single use, single use of other antidepressants and use of ≥ 2 antidepressants. The contribution of antidepressants to the change in biannual suicide rates was analyzed by decomposition analysis.Results: There were 1,277 suicides. About one third of these were on an antidepressant during their last 3 months of life. In the total cohort, the average biannual suicide rate in non-users of antidepressants was 13 per 100,000 person-years. The corresponding figure in users of antidepressants was 34 per 100,000 person-years. These rates were 25, 42 and 65 per 100,000 person-years in users of SSRI, mirtazapine and ≥ 2 antidepressants, respectively. In the total cohort, antidepressant users contributed by 26% to the estimated increase of 7 per 100,000 in biannual suicide rates. In men, biannual suicide rates increased by 11 suicides per 100,000 over the study period; antidepressant users contributed by 25% of the change. In women, those on antidepressant therapy accounted for 29% of the estimated increase of 4.4 per 100,000.Conclusion: Only one third of the oldest Swedish population who died by suicide filled an antidepressant prescription in their last 3 months of life. Higher suicide rates were observed in mirtazapine users compared to those on SSRIs. Users of antidepressants accounted for only one quarter of the increase in the suicide rate. The identification and treatment of suicidal older adults remains an area for prevention efforts.

Objectives(1) To assess the prevalence of depression and treatment rates in antepartum and postpartum women compared to a control group of reproductive-age women over a 12-year period, and (2) To determine demographic characteristics associated with depression.MethodsNational Health and Nutrition Examination Survey data (2007–2018) were used. 5412 controls, 314 antepartum women, and 455 postpartum women were analyzed. Outcomes included depression prevalence, defined as moderate to severe depressive symptoms measured by Patient Health Questionnaire-9 (PHQ-9) scores ≥10 or self-reported antidepressant use; and treatment, defined as antidepressant prescription and/or mental health care services in the past 12 months. Multivariable logistic regression adjusted for age, insurance, race/ethnicity, education, and marital status estimated odds ratios and 95% confidence intervals.ResultsDepression prevalence was 20.2% in controls (95% CI 18.5–21.9), 9.7% in antepartum (6.3–14.1), and 12.8% in postpartum women (9.3–17.1). Mental health care service utilization increased for postpartum women in 2017–2018 (22.0%, 10.6–37.7). In those with depression, control and postpartum groups had similar treatment rates (70%, p = 0.894) compared to antepartum women (51%, p = 0.051). Antidepressant use was the most common treatment reported in all groups. Those who were married or had private insurance had the lowest depression rates in their respective categories. After adjusting for confounders, antepartum and postpartum women had lower odds of depression compared to controls. When the outcome was PHQ-9 ≥ 10 alone, these associations persisted.ConclusionIn a nationally representative sample, depression prevalence was lower in perinatal women compared to reproductive-age controls, and treatment rates were lowest in antepartum women with prevalent depression. Mental health care services may have increased for postpartum women due to the US Preventive Services Task Force 2016 recommendations, which endorsed psychotherapy for postpartum women. Even so, antidepressants were the most reported treatment among perinatal women, despite psychotherapy being the first-line recommended treatment for this population.

Based on pharmacy claims of those who filled at least one prescription for mental health medication in 2019, nearly twice as many teenage girls take antidepressants compared to teenage boys. This statistic shows the percentage of teenagers (excluding those on government-sponsored benefits) who filled a prescription for antidepressants in the U.S. from 2015 to 2019, by gender.

The size of the Global Postpartum Depression Drugs market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 30.00% during the forecast period.Postpartum depression, also known as PPD, is a very common mental health condition in women after childbirth. It involves feelings of sadness, anxiety, and hopelessness that can severely affect normal day-to-day functioning and bonding with the newborn. These are the drugs to help alleviate postpartum depression symptoms and overall well-being.These drugs are frequently antidepressants and work by regulating chemicals in the brain called neurotransmitters. They may decrease the amounts of anxiety and depression and also promote sleep. Examples of commonly used antidepressants include selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and tricyclic antidepressants. Increased awareness about mental health disorders, increased prevalence of PPD, and innovation in pharmaceutical research are some factors driving the postpartum depression drugs market.The demand for the drugs is expected to surge with more women seeking proper treatment options for PPD. The market will rise further with new and improved medication with fewer side effects. Recent developments include: In May 2022, eIntegrity, a Health Education England program in partnership with the NHS and professionals, launched a new program for Perinatal Mental Health., In March 2022, Providence, a United States-based organization, launched a behavioral health program for new moms and their babies. The Perinatal RISE Program (P-RISE) is an intensive outpatient resource specifically for people who are pregnant or up to one year post-partum.. Key drivers for this market are: Surge in Product Launches Coupled with Frequent Product Approvals, Increase in Research and Development Activities; Increase in Awareness about Postpartum Depression (PPD). Potential restraints include: Excessive Cost of PPD Drugs. Notable trends are: Postpartum Anxiety by Type is Expected to Witness Growth Over the Forecast Period.

Postpartum Depression Therapeutics Market Outlook

The global postpartum depression therapeutics market size was valued at approximately USD 3.5 billion in 2023 and is projected to reach around USD 6.5 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.2% during the forecast period. This growth is driven by various factors, including increasing awareness of mental health issues related to childbirth, enhanced healthcare infrastructure, and a rise in the number of women seeking treatment for postpartum depression. The heightened awareness among healthcare professionals and the general public has significantly contributed to the market's expansion, as the stigma surrounding mental health, particularly postpartum depression, is gradually diminishing. More women are now coming forward to seek treatment, which is a crucial growth factor in this market.

The growing recognition of postpartum depression as a critical public health issue has led to increased funding and research initiatives, further propelling market growth. The pharmaceutical industry is investing significantly in research and development to create more effective treatment options, including novel therapeutics that address the unique needs of postpartum women. Additionally, the role of government interventions in promoting maternal mental health cannot be overstated. Many countries have started to integrate mental health services into their maternal health programs, ensuring that women receive comprehensive care during and after pregnancy. This integration is expected to drive demand for therapeutics that can effectively manage the symptoms of postpartum depression.

Technological advancements in healthcare, particularly in telemedicine and digital health platforms, have also facilitated the growth of the postpartum depression therapeutics market. Telemedicine enables easier access to mental health professionals, which is crucial for new mothers who may face logistical challenges in seeking in-person therapy or consultations. Digital health platforms are providing innovative solutions such as mental health apps, which offer support and treatment options for postpartum depression, catering to the growing demand for accessible and convenient healthcare services. Furthermore, the increasing adoption of personalized medicine, which allows for tailored treatment plans based on individual patient profiles, is expected to enhance treatment outcomes and boost market growth.

Regionally, the market is witnessing significant growth in North America and Europe, where awareness of postpartum depression is high, and healthcare systems are well-equipped to handle mental health issues. However, emerging markets in Asia Pacific and Latin America are showing promising growth potential due to increasing healthcare investments and rising awareness levels. The Asia Pacific region, in particular, is experiencing a steady rise in the adoption of postpartum depression therapeutics, driven by factors such as urbanization, increased healthcare access, and changing societal attitudes towards mental health. These regions represent untapped opportunities for market players looking to expand their presence globally.

In parallel with the advancements in postpartum depression therapeutics, the market for Postpartum Bleeding Drug Sales is also gaining traction. This segment is crucial as postpartum hemorrhage remains one of the leading causes of maternal mortality worldwide. The demand for effective drugs to manage and treat postpartum bleeding is increasing, driven by heightened awareness and improved healthcare access. Pharmaceutical companies are investing in research to develop safer and more efficient drugs, which are essential in reducing the incidence of severe bleeding after childbirth. The integration of these drugs into maternal healthcare programs is expected to enhance patient outcomes and support the overall well-being of new mothers.

Treatment Type Analysis

The treatment type segment of the postpartum depression therapeutics market encompasses various options, including antidepressants, hormone therapy, psychotherapy, and others. Antidepressants are frequently prescribed due to their efficacy in managing depressive symptoms, making them a cornerstone of postpartum depression treatment. The demand for antidepressants is expected to remain strong throughout the forecast period as they offer a pharmacological approach that can be tailored to individual patient needs. The development of newer antidepressants with

Based on pharmacy claims in 2019, the highest prevalence of anti-anxiety medication use was seen among women aged 45 to 64 years, with around 10 percent filling at least one prescription in 2019, twice the rate seen among men in the same age group. This statistic shows the percentage of individuals (excluding those on government-sponsored benefits) who filled a prescription for anti-anxiety medication in the U.S. in 2019, by age group and gender.

Objective: To assess whether the use of antidepressants with strong inhibition of serotonin reuptake is associated with a decreased incidence of ischemic stroke and myocardial infarction (MI).

Methods: We conducted a cohort study using the United Kingdom Clinical Practice Research Datalink and considering new users of selective serotonin reuptake inhibitors (SSRIs) or third-generation antidepressants aged ≥18 years between 1995 and 2014. Using a nested case-control approach, each case of a first ischemic stroke or MI identified during follow-up was matched with up to 30 controls on age, sex, calendar time, and duration of follow-up. We estimated incidence rate ratios (RRs) and 95% confidence intervals (CIs) of each outcome associated with current use of strong compared with weak inhibitors of serotonin reuptake using conditional logistic regression.

Results: The cohort included 938,388 incident users of SSRIs (n = 868,755) or third-generation antidepressants (n = 69,633). Mean age at cohort entry was 46 years (64% women). During follow-up, 15,860 cases of ischemic stroke and 8626 cases of MI were identified and matched to 473,712 and 258,022 controls, respectively. Compared with current use of weak inhibitors of serotonin reuptake, current use of strong inhibitors was associated with a decreased rate of ischemic stroke (RR, 0.88; 95% CI 0.80-0.97), but the effect size was smaller in some sensitivity analyses. The rate of MI was similar between strong versus weak inhibitors (RR, 1.00; 95% CI, 0.87-1.15).

Conclusion: Our large population-based study suggests that antidepressants strongly inhibiting serotonin reuptake could modestly decrease the rate of ischemic stroke.

Premenstrual Dysphoric Disorder (PMDD) Market Outlook

The Premenstrual Dysphoric Disorder (PMDD) market is witnessing significant growth, with its global market size projected to expand from USD 1.2 billion in 2023 to approximately USD 2.3 billion by 2032, at a compound annual growth rate (CAGR) of 7.3%. This robust growth trajectory is largely driven by increasing awareness about PMDD as a severe form of premenstrual syndrome (PMS) that affects a significant portion of the female population globally. The increasing acceptance of PMDD as a diagnosable medical condition requiring specific treatment interventions is a crucial growth factor in this market. Moreover, the ongoing research and development activities aimed at discovering effective treatment modalities are further propelling the market's expansion. Additionally, a growing number of healthcare professionals are recognizing the importance of individualized treatment plans, which is fostering the demand for diverse therapeutic options.

One of the primary growth drivers in the PMDD market is the increasing prevalence of PMDD among women of reproductive age. Awareness campaigns and educational programs spearheaded by healthcare organizations and advocacy groups have significantly contributed to this heightened awareness, resulting in more women seeking medical help. The recognition of PMDD as a distinct disorder with specific diagnostic criteria in medical literature has also played a critical role. Furthermore, the advent of novel pharmacological treatments, including advanced antidepressants and hormonal therapies, has broadened the therapeutic landscape, thus offering more targeted and effective solutions. The pharmaceutical industry sees this as a lucrative opportunity, which is reflected in increased research and development expenditures directed towards innovation in PMDD treatments.

The demographic shift towards a higher proportion of working women has also influenced the demand for PMDD treatment. The stressors associated with balancing work and personal life can exacerbate PMDD symptoms, prompting women to seek more effective remedies. This trend is coupled with a growing societal acceptance of discussing mental health issues openly, including PMDD, which is gradually reducing the stigma associated with seeking treatment. Moreover, the rise of telemedicine and digital health platforms is facilitating easier access to healthcare resources, enabling women to receive timely advice and prescriptions, thereby contributing to market growth. The increasing demand for personalized treatment regimens tailored to individual patient needs is another factor bolstering market expansion.

Regionally, North America holds a dominant position in the PMDD market, mainly due to the high awareness of women's health issues and the availability of advanced healthcare infrastructure. Europe follows closely, with significant contributions from countries like the UK, Germany, and France, where the prevalence of PMDD is increasingly recognized, and healthcare systems are well-equipped to manage such conditions. The Asia Pacific region, however, is expected to exhibit the highest growth rate during the forecast period, driven by an increasing number of women seeking medical attention for menstrual-related disorders. The growing healthcare infrastructure and rising awareness in countries like India and China are key to this expansion. Meanwhile, Latin America and the Middle East & Africa are witnessing gradually increasing attention to PMDD, supported by improved healthcare access and international collaboration in research initiatives.

Treatment Type Analysis

The treatment type segment of the Premenstrual Dysphoric Disorder (PMDD) market is diversified, encompassing antidepressants, hormonal therapy, nutritional supplements, and other treatments. Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), are the most commonly prescribed treatment for PMDD due to their efficacy in alleviating severe mood-related symptoms. SSRIs function by balancing serotonin levels in the brain, which are often disrupted in patients with PMDD, leading to an improvement in mood and emotional well-being. The efficacy of these medications is well-documented, and they have become the first line of treatment, especially for patients experiencing severe depressive symptoms. The market for antidepressants in PMDD is poised for steady growth as pharmaceutical companies continue to innovate, introducing newer formulations with fewer side effects.

Hormonal therapy is another critical component in the treatment of PMDD, targeting the hormonal fluctuations that are

According to the data, in Italy, almost 31 percent of patients with a diagnosis of depression used antidepressants in 2021. Women diagnosed with depression had a higher prevalence of antidepressant use compared to men. This statistic shows the prevalence of antidepressant consumption in Italy in 2021, by gender.

Adjusted logistic regression results for primary outcome of depression prevalence.

During the 2023-2024 school year, 33 percent of university and college students in the U.S. reported that in the past year they had been using antidepressant medications regularly. This statistic shows the percentage of postsecondary students using psychotropic medications in the United States in 2023-2024.

Depression prevalence (PHQ-9 ≥ 10 or antidepressant prescription) by study group characteristics.

BackgroundAntidepressant drug treatment may be associated with weight gain, but long-term studies are lacking.MethodsWe included 3,127 adults (1,701 women) from the REGICOR study, aged 55.6 (SD = 11.6) years on average in 2003–2006, living in the northeast of Spain. They had data at two time points (baseline and a median of 6.3 years later) on self-reported antidepressant use, body weight and height, and on baseline smoking, physical activity, diet quality, education, civil status, and depressive symptoms assessed with the Patient Health Questionnaire (PHQ-9) at follow-up. We defined four trajectories of antidepressant use as follows: never use, new use at follow-up, initial use discontinued, repeated use at both time points. We used multivariable linear models to estimate the association of these trajectories with the percentage of weight change. In people without obesity at baseline (n = 2,404), we also estimated the association with obesity incidence at follow-up.ResultsThe average 6-year weight gain was 0.53 kg (1.01% body weight), and 24.5% of the participants gained >5% of body weight. The majority (83.6%) of participants did not report any use of antidepressants, 6.2% initiated during follow-up, 5.1% discontinued it, and 5.1% reported their use at both time points. In multivariable analyses, compared to never users, all trajectories were associated with greater weight gain: +1.78% (0.57, 2.98) for initial use discontinued, +2.08% (0.97, 3.19) for new use at follow-up, and +1.98% (95% CI: 0.75, 3.20) for repeated use. In non-obese participants at baseline (n = 2,404), the odds ratio for becoming obese was 2.06 (1.03, 3.96) for repeated use and non-statistically significant for the other trajectories.ConclusionsIn a population-based adult cohort, repeated use of antidepressants was strongly associated with weight gain. New and discontinued use was associated with weight gain, but non-significantly to obesity incidence. Given the global obesity epidemic and the widespread use of antidepressants, weight management and metabolic monitoring should be encouraged and integrated into depression follow-up guidelines alongside antidepressant prescriptions.